The European Medicines Agency has been formally notified by Janssen-Cilag International NV of its decision to withdraw its application for a centralised marketing authorisation for the medicine Comfyde (carisbamate) 100mg, 200mg, 400mg and 600mg film-coated tablets. This medicine was intended to be used for adjunctive treatment of partial onset seizures with or without secondary generalisation …

See original here: 
Janssen-Cilag International NV Withdraws Its Marketing Authorisation Application For Comfyde (Carisbamate), Europe (Medical News Today)

Tags: adjunctive-treatment, article directory, Article Marketing, comfyde, european, formally-notified, human, medicine, safety-review, the-best

This entry was posted on January 21, 2010 at 8:29 am. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.

Posted in Article Marketing by No Comments Yet